HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 3,049-3,060 of 4,505
Behavioral study icon
CompletedNCT06206798

Resourcefulness Group Intervention on Recovery and Quality of Life

Official study title

The Effects of Resourcefulness Group Intervention on Recovery and Quality of Life in Patients With Chronic Schizophrenia.

This study has finished and is no longer accepting participants.

In New Taipei City
SchizophreniaBehavioural studyAges 20–64
Countries
Taiwan
Sponsor
National Taipei University of Nursing and Health Sciences
Drug study icon
CompletedNCT01295372

Zicronapine Compared With Risperidone and Metabolic Changes

About this title

Safety and Efficacy of Zicronapine in Patients With Schizophrenia

Read the official source — NCT01295372
What is this study about?

Researchers compared Zicronapine and Risperidone to find out how the approaches affected body weight in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Brno
SchizophreniaMedication studyAges 18–65
Countries
France, Czechia, Estonia, + 2 others
Sponsor
H. Lundbeck A/S
Drug study icon
TerminatedNCT00257192

Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia

Official study title

Six Week, Double-Blind, Placebo Controlled Phase III Trial Evaluating The Efficacy, Safety And Pharmacokinetics Of Flexible Doses Of Oral Ziprasidone In Adolescent Subjects With Schizophrenia

This study ended early.

Multiple locations, including Birmingham
SchizophreniaMedication studyAges 13–17
Countries
United States, Colombia, Costa Rica, + 6 others
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Drug study icon
TerminatedNCT01900522

Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia

Official study title

A Phase 1, Randomized, Placebo- Controlled, Double-Blind Safety, Tolerability, Pharmacokinetic, and Exploratory Pharmacodynamic Study in Healthy Subjects and Subjects With Stable Schizophrenia After Multiple Doses of ITI-214

This study ended early.

Multiple locations, including Glendale
SchizophreniaMedication studyAges 18+
Countries
United States
Sponsor
Takeda
Drug study icon
CompletedNCT02773576

Safety and Tolerability of Risperidone Implants

What is this study about?

Researchers studied Risperidone implant, tracking side effects to assess safety and tolerability in people with schizophrenia.

This study has finished and is no longer accepting participants.

In Garden Grove
SchizophreniaMedication studyAges 18–70
Countries
United States
Sponsor
Braeburn Pharmaceuticals
Drug study icon
TerminatedNCT00265382

Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia

Official study title

26-Week Open-Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Adolescent Subjects With Schizophrenia

This study ended early.

Multiple locations, including Birmingham
SchizophreniaMedication studyAges 13–17
Countries
United States, Colombia, Costa Rica, + 6 others
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Drug study icon
TerminatedNCT02968121

Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia

Official study title

A Phase 1, Two-part, Open-label, Randomized, Exploratory and Single Ascending Dose, Parallel Arm Trial to Determine the Pharmacokinetics, Safety, and Tolerability of Brexpiprazole Long-acting Injectable Administered Subcutaneously or Intramuscularly in Adult Subjects With Schizophrenia

This study ended early.

Multiple locations, including Garden Grove
SchizophreniaMedication studyAges 18–64
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
Drug study icon
CompletedNCT01552772

Aripiprazole Injection After Oral Antipsychotic Treatment: Safety Study

About this title

Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole

Read the official source — NCT01552772
What is this study about?

Researchers studied Aripiprazole IM Depot, tracking side effects to assess safety and tolerability in adults with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Anaheim
SchizophreniaMedication studyAges 18–64
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.